Cumulus Neuroscience Expands its Vision into the Japanese Market Through Collaboration with Shionogi & Co., Ltd.
Cumulus Neuroscience, a pioneering player in digital health focusing on improving clinical trials and patient management in the neuroscience domain, has taken a significant step by entering the Japanese market. This expansion is in partnership with Shionogi & Co., Ltd., a prominent research-focused pharmaceutical entity based in Japan. This collaboration marks Cumulus' first venture into Asia's biopharma space, tapping into a crucial market that is pivotal for advancing neurology and neuropsychiatric care.
Shionogi plans to utilize the Cumulus NeuLogiq® Platform to obtain objective neurophysiological data for their novel therapeutic agent, S-898270. This compound has been designed to selectively inhibit phosphodiesterase-4D (PDE4D), which is believed to aid both early and late stages of memory formation. The planned study will be conducted in Japan, showcasing the significant potential of the NeuLogiq platform in the growing Asian biopharma landscape.
To ensure that the transition into this new market is successful, Cumulus has taken several proactive steps. The NeuLogiq Platform has been aptly translated into Japanese, making it accessible for local researchers and participants. Additionally, Cumulus has assembled a dedicated team in Japan to facilitate clinical trial operations, aligning with local standards and regulations, thus ensuring smooth project execution.
The NeuLogiq® Platform stands out in the biopharma sector due to its AI-driven approach, designed in collaboration with ten leading pharmaceutical companies around the globe. It offers a suite of advanced tools geared toward enhancing the discovery and development of therapies targeting neurodegenerative and neuropsychiatric conditions. Brian Murphy, PhD, who co-founded Cumulus, expressed enthusiasm about the collaboration, stating that Shionogi’s approach to integrating NeuLogiq digital endpoints into the clinical study protocol is promising. Their ongoing work, including the CNS-101 observational study presented at the Alzheimer's Association International Conference 2025, underscores the platform's ability to provide more sensitive measures of disease progression compared to conventional cognitive scales currently in use.
The initial collaboration between Cumulus and Shionogi was outlined through a focused study startup project. This project's goal is to seamlessly incorporate NeuLogiq's EEG and cognitive biomarkers into the S-898270 Phase 1 study protocol. This study will utilize available preclinical data and recognizable scientific literature, with the ongoing enrollment of healthy controls expected to ramp up in early 2026. This approach underscores Cumulus’ commitment to enhancing patient monitoring precision and ensuring that clinical trials yield reliable outcomes across diverse brain functions.
Furthermore, Cumulus is dedicated to promoting precision in Central Nervous System (CNS) clinical trials for various industry partners. The company's capabilities enable remote patient monitoring across multiple aspects of brain function. As the ongoing battle against Alzheimer’s disease continues—affecting millions worldwide—Cumulus Neuroscience is positioned at the forefront of developing tools that can transform patient care and improve diagnostic capabilities.
About Cumulus Neuroscience: Cumulus is unwavering in its mission to harness data and insights for accelerating diagnosis and management of CNS disorders. The overhead of the NeuLogiq platform not only supports decentralized trials, but is also vital in creating a robust standard for real-world assessment of disease progression. By harnessing a combination of patented technology, giving rise to extensive longitudinal data collection, and applying machine learning analytics, Cumulus aims to enhance the robustness of neuroscience clinical trials dramatically.
About Shionogi & Co., Ltd.: Established over 146 years ago, Shionogi has made it its mission to offer the best possible medicines for the health and welfare of patients globally. With expertise in several therapeutic fields, including central nervous system disorders, Shionogi reinforces its commitment to groundbreaking research and development, striving to address complicated health challenges facing communities today. For additional details on Shionogi’s research initiatives and product portfolios, visit their official website.
Shionogi plans to utilize the Cumulus NeuLogiq® Platform to obtain objective neurophysiological data for their novel therapeutic agent, S-898270. This compound has been designed to selectively inhibit phosphodiesterase-4D (PDE4D), which is believed to aid both early and late stages of memory formation. The planned study will be conducted in Japan, showcasing the significant potential of the NeuLogiq platform in the growing Asian biopharma landscape.
To ensure that the transition into this new market is successful, Cumulus has taken several proactive steps. The NeuLogiq Platform has been aptly translated into Japanese, making it accessible for local researchers and participants. Additionally, Cumulus has assembled a dedicated team in Japan to facilitate clinical trial operations, aligning with local standards and regulations, thus ensuring smooth project execution.
The NeuLogiq® Platform stands out in the biopharma sector due to its AI-driven approach, designed in collaboration with ten leading pharmaceutical companies around the globe. It offers a suite of advanced tools geared toward enhancing the discovery and development of therapies targeting neurodegenerative and neuropsychiatric conditions. Brian Murphy, PhD, who co-founded Cumulus, expressed enthusiasm about the collaboration, stating that Shionogi’s approach to integrating NeuLogiq digital endpoints into the clinical study protocol is promising. Their ongoing work, including the CNS-101 observational study presented at the Alzheimer's Association International Conference 2025, underscores the platform's ability to provide more sensitive measures of disease progression compared to conventional cognitive scales currently in use.
The initial collaboration between Cumulus and Shionogi was outlined through a focused study startup project. This project's goal is to seamlessly incorporate NeuLogiq's EEG and cognitive biomarkers into the S-898270 Phase 1 study protocol. This study will utilize available preclinical data and recognizable scientific literature, with the ongoing enrollment of healthy controls expected to ramp up in early 2026. This approach underscores Cumulus’ commitment to enhancing patient monitoring precision and ensuring that clinical trials yield reliable outcomes across diverse brain functions.
Furthermore, Cumulus is dedicated to promoting precision in Central Nervous System (CNS) clinical trials for various industry partners. The company's capabilities enable remote patient monitoring across multiple aspects of brain function. As the ongoing battle against Alzheimer’s disease continues—affecting millions worldwide—Cumulus Neuroscience is positioned at the forefront of developing tools that can transform patient care and improve diagnostic capabilities.
About Cumulus Neuroscience: Cumulus is unwavering in its mission to harness data and insights for accelerating diagnosis and management of CNS disorders. The overhead of the NeuLogiq platform not only supports decentralized trials, but is also vital in creating a robust standard for real-world assessment of disease progression. By harnessing a combination of patented technology, giving rise to extensive longitudinal data collection, and applying machine learning analytics, Cumulus aims to enhance the robustness of neuroscience clinical trials dramatically.
About Shionogi & Co., Ltd.: Established over 146 years ago, Shionogi has made it its mission to offer the best possible medicines for the health and welfare of patients globally. With expertise in several therapeutic fields, including central nervous system disorders, Shionogi reinforces its commitment to groundbreaking research and development, striving to address complicated health challenges facing communities today. For additional details on Shionogi’s research initiatives and product portfolios, visit their official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.